Halozyme Therapeutics Inc. (HALO)’s financial ratios: A comprehensive overview

In the latest session, Halozyme Therapeutics Inc. (NASDAQ: HALO) closed at $34.93 down -3.08% from its previous closing price of $36.04. In other words, the price has decreased by -$1.11 from its previous closing price. On the day, 1866616 shares were traded.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.


For a deeper understanding of Halozyme Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.05. For the most recent quarter (mrq), Quick Ratio is recorded 6.51 and its Current Ratio is at 7.63. In the meantime, Its Debt-to-Equity ratio is 6.14 whereas as Long-Term Debt/Eq ratio is at 6.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 24, 2023, initiated with a Buy rating and assigned the stock a target price of $61.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 17 when LaBarre Michael J. sold 10,000 shares for $36.00 per share. The transaction valued at 360,000 led to the insider holds 151,911 shares of the business.

LaBarre Michael J. sold 10,000 shares of HALO for $360,000 on Jan 16. The SVP, CHIEF TECHNICAL OFFICER now owns 151,911 shares after completing the transaction at $36.00 per share. On Dec 13, another insider, LaBarre Michael J., who serves as the SVP, CHIEF TECHNICAL OFFICER of the company, sold 10,000 shares for $40.39 each. As a result, the insider received 403,940 and left with 151,911 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 4.76B and an Enterprise Value of 5.78B. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.64, and their Forward P/E ratio for the next fiscal year is 10.11. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.91 while its Price-to-Book (P/B) ratio in mrq is 18.51. Its current Enterprise Value per Revenue stands at 7.46 whereas that against EBITDA is 14.87.

Stock Price History:

Over the past 52 weeks, HALO has reached a high of $53.71, while it has fallen to a 52-week low of $29.85. The 50-Day Moving Average of the stock is 38.04, while the 200-Day Moving Average is calculated to be 37.47.

Shares Statistics:

For the past three months, HALO has traded an average of 1.19M shares per day and 2.1M over the past ten days. A total of 135.15M shares are outstanding, with a floating share count of 130.79M. Insiders hold about 0.99% of the company’s shares, while institutions hold 93.52% stake in the company. Shares short for HALO as of Dec 28, 2023 were 7.35M with a Short Ratio of 7.35M, compared to 7.13M on Nov 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.56% and a Short% of Float of 6.58%.

Earnings Estimates

There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.82 for the current quarter, with a high estimate of $0.86 and a low estimate of $0.75, while EPS last year was $0.48. The consensus estimate for the next quarter is $0.85, with high estimates of $0.88 and low estimates of $0.83.

Analysts are recommending an EPS of between $2.8 and $2.7 for the fiscal current year, implying an average EPS of $2.76. EPS for the following year is $3.49, with 5 analysts recommending between $3.86 and $3.05.

Revenue Estimates

A total of 8 analysts believe the company’s revenue will be $235.41M this quarter.It ranges from a high estimate of $242.26M to a low estimate of $230.49M. As of the current estimate, Halozyme Therapeutics Inc.’s year-ago sales were $181.5M, an estimated increase of 29.70% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $239.11M, an increase of 36.20% over than the figure of $29.70% in the same quarter last year. There is a high estimate of $283.02M for the next quarter, whereas the lowest estimate is $219.19M.

A total of 9 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $841.47M, while the lowest revenue estimate was $829.7M, resulting in an average revenue estimate of $834.57M. In the same quarter a year ago, actual revenue was $660.12M, up 26.40% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $1.04B in the next fiscal year. The high estimate is $1.26B and the low estimate is $948.2M. The average revenue growth estimate for next year is up 25.10% from the average revenue estimate for this year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular